Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, controlled, open label, multi-center phase III trial comparing the safety and antiviral activity of a protease-containing regimen (d4T/ddI/IDV/RTV) [stavudine + didanosine + indinavir + ritonavir] versus a protease-sparing regimen (d4T/ddI/EFV) [stavudine + didanosine + efavirenz] and the ability of interleukin-2 to purge HIV from latent stores in patients with acute/early HIV infection

Next Previous
X
Search
Trial Profile

Randomized, controlled, open label, multi-center phase III trial comparing the safety and antiviral activity of a protease-containing regimen (d4T/ddI/IDV/RTV) [stavudine + didanosine + indinavir + ritonavir] versus a protease-sparing regimen (d4T/ddI/EFV) [stavudine + didanosine + efavirenz] and the ability of interleukin-2 to purge HIV from latent stores in patients with acute/early HIV infection

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efavirenz (Primary) ; Indinavir (Primary) ; Ritonavir (Primary) ; Abacavir; Didanosine; Interleukin-2; Stavudine
  • Indications HIV infections
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Sep 2013 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 28 Sep 2008 Planned initiation date (Sep 2009) added as reported by CT.gov
    • 28 Sep 2008 Planned end date (Sep 2010) added as reported by CT.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top